Therapeutic Area: Oncology
Characterization of Expanded Gamma Delta T Cells from Atypical X-SCID Patient Reveals Preserved Function and IL2RG-Mediated Signaling
Tuovinen EA, et al.
JCI
November 2022
Authors and Affiliates
Elina A Tuovinen 1 2 3, Sakari Pöysti # 4, Firas Hamdan # 1 5 6, Kim My Le 1 3, Salla Keskitalo 7, Tanja Turunen 7, Léa Minier 1 8, Nanni Mamia 1 3, Kaarina Heiskanen 3 9, Markku Varjosalo 7, Vincenzo Cerullo 1 5 6, Juha Kere 2 10 11, Mikko R J Seppänen 1 3 12, Arno Hänninen 4, Juha Grönholm 13 14;
1Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
2Folkhälsan Research Center, Helsinki, Finland.
3Pediatric Research Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
4Department of Clinical Microbiology and Immunology, Turku University Hospital, Turku, Finland.
5Drug Research Program Helsinki (DRP), Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
6Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland.
7Systems Biology Research Group and Proteomics Unit, Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.
8Faculty of Science and Technology, University of Lille, Lille, France.
9Children's Immunodeficiency Unit, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
10Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
11Stem Cells and Metabolism Research Program, University of Helsinki, Helsinki, Finland.
12Rare Diseases Center and Pediatric Research Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
13Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. juha.gronholm@helsinki.fi.
14Pediatric Research Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland. juha.gronholm@helsinki.fi.
#Contributed equally.
Evolution and modulation of antigen-specific T cell responses in melanoma patients
Authors and Affiliates
Jani Huuhtanen 1 2 3 4, Liang Chen 5 6, Emmi Jokinen 4, Henna Kasanen 1 2 3, Tapio Lönnberg 7 8, Anna Kreutzman 1 2 3, Katriina Peltola 3 9, Micaela Hernberg 9, Chunlin Wang 5 6, Cassian Yee 10 11, Harri Lähdesmäki 4, Mark M Davis 12 13 14, Satu Mustjoki 15 16 17 18;
1Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
2Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
3iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
4Department of Computer Science, Aalto University, Espoo, Finland.
5Department of Immunology and Microbiology, Stanford University, Stanford, CA, USA.
6Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
7Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
8InFLAMES Research Flagship Center, University of Turku, Turku, Finland.
9Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
10Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
11Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
12Department of Immunology and Microbiology, Stanford University, Stanford, CA, USA. mmdavis@stanford.edu.
13Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA. mmdavis@stanford.edu.
14Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA. mmdavis@stanford.edu.
15Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. satu.mustjoki@helsinki.fi.
16Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. satu.mustjoki@helsinki.fi.
17iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. satu.mustjoki@helsinki.fi.
18Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. satu.mustjoki@helsinki.fi.
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma
Ravindranathan S, et al.
November 2022
Authors and Affiliates
Sruthi Ravindranathan 1,2, Tenzin Passang 3,4, Jian-Ming Li 3,4, Shuhua Wang 3,4, Rohan Dhamsania 3,4, Michael Brandon Ware 3,4, Mohammad Y Zaidi 3,4, Jingru Zhu 3,4, Maria Cardenas 5, Yuan Liu 4,6, Sanjeev Gumber 7,8, Brian Robinson 7, Anish Sen-Majumdar 9, Hanwen Zhang 3, Shanmuganathan Chandrakasan 10, Haydn Kissick 4,5,11, Alan B Frey 9, Susan N Thomas 12,13, Bassel F El-Rayes 3,4, Gregory B Lesinski 3,4, Edmund K Waller 14,15;
1 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
2 Winship Cancer Institute, Emory University, Atlanta, GA, USA.
3 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
4 Winship Cancer Institute, Emory University, Atlanta, GA, USA.
5 Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
6 Rollins School of Public Health, Emory University, Atlanta, GA, USA.
7 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
8 Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
9 Cambium Oncology LLC, Atlanta, GA, USA.
10 Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA.
11 Emory Vaccine Centre, Emory University, Atlanta, GA, USA.
12 Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
13 Parker H. Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA.
14 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
15 Winship Cancer Institute, Emory University, Atlanta, GA, USA.
A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC
Authors and Affiliates
Laurel B Darragh 1,2, Michael M Knitz 1, Junxiao Hu 3, Eric T Clambey 4, Jennifer Backus 1, Andrew Dumit 1, Von Samedi 5, Andrew Bubak 6, Casey Greene 3,7, Timothy Waxweiler 1, Sanjana Mehrotra 5, Shilpa Bhatia 1, Jacob Gadwa 1, Thomas Bickett 1, Miles Piper 1, Kareem Fakhoury 1, Arthur Liu 8, Joshua Petit 8, Daniel Bowles 9, Ashesh Thaker 10, Kimberly Atiyeh 11, Julie Goddard 12, Robert Hoyer 9, Adrie Van Bokhoven 5, Kimberly Jordan 2, Antonio Jimeno 9, Angelo D'Alessandro 7, David Raben 1, Jessica D McDermott 9, Sana D Karam 13,14;
1 Radiation Oncology, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA.
2 Department of Immunology, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA.
3 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.
4 Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
5 Department of Pathology, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA.
6 Department of Neurology, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA.
7 Department of Biochemistry and Molecular Genetics, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA.
8 Department of Radiation Oncology, University of Colorado, Poudre Valley Hospital, Fort Collins, CO, USA.
9 Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA.
10 Department of Radiology, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA.
11 Department of Otolaryngology Head and Neck Surgery, University of Colorado, Memorial South Hospital, Colorado Springs, CO, USA.
12 Department of Otolaryngology Head and Neck Surgery, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA.
13 Radiation Oncology, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA. sana.karam@cuanschutz.edu.
14 Department of Immunology, University of Colorado Denver at Anschutz Medical Campus, Aurora, CO, USA. sana.karam@cuanschutz.edu.
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates
Singh S, et al.
OncoImmunology
November 2022
Authors and Affiliates
Shailbala Singh 1, Leticia C Clemente 2, Edwin R Parra 2, Amanda Tchakarov 3, Chao Yang 4, Yisheng Li 4, James P Long 4, Cassian Yee 1,5, Jamie S Lin 6;
1 Department of Melanoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2 Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3 Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School, Houston, TX, USA.
4 Department of Biostatistics, Division of Basic Sciences, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5 Department of Immunology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
6 Section of Nephrology, Division of Internal Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Merryman RW, et al.
Blood Advances
November 2022
Authors and Affiliates
Reid W. Merryman1, Robert A. Redd2, Eleanor Taranto3, Gulrayz Ahmed4, Erin Jeter1, Kristin M. McHugh1 4 , Jennifer R. Brown1, Jennifer L. Crombie1, Matthew S. Davids1, David C. Fisher1, Arnold S. Freedman1 5 , Eric Jacobsen1, Caron A. Jacobson1, Austin I. Kim1, Ann S. LaCasce1, Samuel Y. Ng1, Oreofe O. Odejide1 6 , Erin M. Parry1, Heather Jacene5, Hyesun Park5, Parastoo B. Dahi6, Yago Nieto7, Robin M. Joyce8, Yi-Bin Chen9 7 , Margaret A. Shipp1, Alex F. Herrera10*, and Philippe Armand1 8 *
1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 2 Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 3 Department of Medicine, Brigham and Women's Hospital, Boston, MA 4 Medical College of Wisconsin, Milwaukee, WI 5 Department of Imaging/Radiology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA 6 Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY 7 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 8 Department of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA 9 Bone Marrow Transplantation Program, Massachusetts General Hospital, Boston, MA 10 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA *These authors contributed equally to this work.
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.
Gill S, et al.
Blood Advances
November 2022
Authors and Affiliates
Saar Gill,1,2 Vanessa Vides,3 Noelle V. Frey,1 Elizabeth O. Hexner,1,2 Susan Metzger,2 Megan O’Brien,2 Wei-Ting Hwang,4 Jennifer L. Brogdon,5 Megan M. Davis,2 Joseph A. Fraietta,2,6,9 Avery L. Gaymon,2 Whitney L. Gladney,2 Simon F. Lacey,2 Anne Lamontagne,2 Anthony R. Mato,1 Marcela V. Maus,7 J. Joseph Melenhorst,2,6,9 Edward Pequignot,2 Marco Ruella,1,2 Maksim Shestov,1,2 John C. Byrd,8 Stephen J. Schuster,1 Donald L. Siegel,2,6 Bruce L. Levine,2,6 Carl H. June,2,6,9 and David L. Porter1
1Cell Therapy and Transplant Program, Division of Hematology-Oncology and Abramson Cancer Center and 2Center for Cellular Immunotherapies, University of Pennsylvania,Philadelphia, PA; 3Pennsylvania State University College of Medicine, Hershey, PA; 4Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania,Philadelphia, PA; 5Novartis Institutes for Biomedical Research, Cambridge, MA; 6Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia,PA; 7Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 8Division of Hematology, The Ohio State University, Columbus, OH; and 9Parker Institute for Cancer Immunotherapy
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Jabbour E, et al.
Lancet Haematology
October 2022
Authors and Affiliates
Elias Jabbour*, Nicholas J Short*, Nitin Jain, Philip A Thompson, Tapan M Kadia, Alessandra Ferrajoli, Xuelin Huang, Musa Yilmaz, Yesid Alvarado, Keyur P Patel, Guillermo Garcia-Manero, Walid Macaron, Rebecca Garris, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian
*These authors contributed equally Department of Leukemia (Prof E Jabbour MD, N J Short MD, N Jain MD, P A Thompson MBBS, Prof T M Kadia MD, Prof A Ferrajoli MD, M Yilmaz MD, Y Alvarado MD, Prof G Garcia-Manero MD, W Macaron MD, R Garris MS, Prof M Konopleva MD PhD, Prof F Ravandi MD, Prof H Kantarjian MD), Department of Biostatistics (Prof X Huang PhD), and Department of Hematopathology (K P Patel MD), The University of Texas MD Anderson Cancer Center, Houston, TX, USA
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells
Lu KH, et al.
September 2022
Authors and Affiliates
Kevin Hai-Ning Lu 1,2,3, Julius Michel 1,2, Michael Kilian 1,2, Katrin Aslan1 ,2,#, Hao Qi 1,2, Niklas Kehl 1,2, Stefanie Jung 1,2, Khwab Sanghvi 1,2, Katharina Lindner 1,3,4, Xin-Wen Zhang 1,2,11, Edward W Green 1,2, Isabel Poschke 4, Miriam Ratliff 5, Theresa Bunse1 ,2, Felix Sahm 6,12, Andreas von Deimling 6,12, Wolfgang Wick 7,8, Michael Platten 1,2,4,9,10, and Lukas Bunse 1,2,*;
1 DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
2 Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
3 Department of Pediatric Hematology and Oncology, Clinic of Pediatrics III, University Hospital Essen, Essen, Germany
4 Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
5 Department of Neurosurgery, University Hospital Mannheim, Mannheim, Germany.
6 Department of Neuropathology, Heidelberg University Medical Center, Heidelberg, Germany.
7 Department of Neurology, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany.
8 DKTK CCU Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
9 Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany.
10 DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim Germany.
11 Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany
12 CCU Neuropathology, DKFZ, DKTK, Heidelberg, Germany.
# presentaddress: Immatics Biotechnologies GmBH, Tübingen, Germany